Solid Tumors

Solid Tumors

If you or a loved one have been diagnosed with an aggressive cancer, a clinical trial studying the potential of a new targeted treatment could be an option. Continue reading to learn more about the trial and see if you are eligible to enroll

How Your Cancer Genetics Can Help You Find Potential Treatment Options

Cancer is caused by changes to specific genes that control how our cells grow and divide. Some cancers are characterized by increased activity of a protein called PTEFb. PTEFb plays a central role in helping cancer cells survive and thrive by increasing levels of specific genes. MYC and MCL1 are some of these genes
Increased MYC is estimated to be involved in over 70% of cancers1. If you aren’t sure if MYC is involved in your or your loved one’s cancer, ask your doctor. He or she can help get genetic testing completed to better understand your cancer

1 Dang CV. MYC on the path to cancer. Cell. 2012;149(1):22-35. doi:10.1016/j.cell.2012.03.003

About the Phase 1 Clinical Trial of VIP152

VIP152 is a PTEFb inhibitor, meaning it works to block the activity of PTEFb. Blocking PTEFb stops a series of signals that can lead to tumor growth, and, as a result, treatment with VIP152 is expected to decrease the production of cancer-promoting genes, such as MYC and MCL1. For patients whose cancers are driven by MYC, blocking PTEFb at the beginning of the pathway which drives cancer growth may be a way to slow or stop tumor growth and disease progression

Tumor Growth & Progression

Controls Tumor Growth & Progression in Preclinal Studies

A Phase 1 clinical trial of VIP152 (VNC-152-101, also called the “study drug”) is studying the safety and preliminary efficacy of VIP152 in solid tumors characterized by MYC overexpression, amplification or translocation. VIP152 is given as a 30-minute IV infusion once weekly until disease progression or no longer tolerated


Ovarian Cancer

Triple Negative Breast Cancer

Castration-resistant neuroendocrine prostate cancer

Other advanced solid tumors with MYC overexpression or amplification


Study Locations

Contact us to
learn more